Cinnamic Acid

Cinnamic Acid

SCHEMBL6444127

O=C(O)C=Cc1ccccc1.[Cu]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.95
HDAC4 P56524 3/20 0.95
HDAC1 Q13547 3/20 0.95
HDAC2 Q92769 3/20 0.95
HDAC8 Q9BY41 3/20 0.95
HDAC6 Q9UBN7 3/20 0.95
HCAR2 Q8TDS4 2/20 0.95
HDAC7 Q8WUI4 2/20 0.95
HDAC10 Q969S8 2/20 0.95
HDAC11 Q96DB2 2/20 0.95
HDAC9 Q9UKV0 2/20 0.95
HDAC5 Q9UQL6 2/20 0.95
TNKS O95271 1/20 0.95
TNKS2 Q9H2K2 1/20 0.95
PLIN1 O60240 2/20 0.70
LMNA P02545 2/20 0.70
MAPT P10636 2/20 0.70
RECQL P46063 2/20 0.70
PLIN5 Q00G26 2/20 0.70
ABHD5 Q8WTS1 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cinnamic Acid SCHEMBL6444122 1.00 HDAC3 (0.95) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL29989544 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL1332 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL1333 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL3406486 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL50466 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL653827 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL1706935 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL653828 0.97 HCAR2 (1.00) HDAC3HDAC4HDAC1HDAC2HDAC8
Cinnamic Acid SCHEMBL988706 0.95 HCAR2 (0.95) HDAC3HDAC4HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5179224-A Reacting a styrene compound, carbon monoxide, an alcohol and oxygen using palladium, copper, metal and chlorine compounds which can be regenerated MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1993-01-12 US claimed
US-4824661-A COPPER SALT, 2,4,4*-TRICHLORO-2*-HYDROXYDIPHENYL ETHER BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) 1989-04-25 US claimed
EP-0038867-B1 TOOTHPASTE Blendax-Werke R. Schneider GmbH & Co. (DE) 1983-09-28 EP claimed
EP-0038868-B1 TOOTHPASTE Blendax-Werke R. Schneider GmbH & Co. (DE) 1983-09-28 EP claimed
US-4339429-A Toothpaste active against plaque comprising a copper compound and a plastic polishing agent BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) 1982-07-13 US claimed
US-4332791-A NONDISCOLORING BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) 1982-06-01 US claimed
CN-119504611-A Method for synthesizing quinazoline derivative by manganese-based catalyst 西安近代化学研究所 2025-02-25 CN disclosed
WO-2023277084-A1 COMPOSITION FOR ORAL CAVITY ライオン株式会社 2023-01-05 WO disclosed
CN-103897494-B Copper film formation composition, copper film forming method, copper film, wiring substrate and electronic equipment JSR株式会社 2017-10-27 CN disclosed
CN-104496914-A Synthesis method of 2-aryl-substituted quinazoline compounds UNIV NORTHWESTERN 2015-04-08 CN disclosed
CN-103897494-A Copper film forming composition, copper film forming method, copper film, wiring substrate and electronic device JSR CORP 2014-07-02 CN disclosed
CN-103664875-A Novel method for synthesizing 1,4,5,6-tetrahydropyrimidine derivative UNIV NORTHWESTERN 2014-03-26 CN disclosed
US-20050054882-A1 Diaryl ether condensation reactions NSF - DEITR 2005-03-10 US disclosed
EP-0323141-A2 Preparation of cinnamate esters MITSUI TOATSU CHEMICALS, Inc. (JP) 1989-07-05 EP disclosed
EP-0177354-B1 PREPARATION PROCESS OF CINNAMATE ESTERS MITSUI TOATSU CHEMICALS, Inc. (JP) 1989-04-19 EP disclosed
EP-0242072-A1 Preparation of cinnamate esters MITSUI TOATSU CHEMICALS, Inc. (JP) 1987-10-21 EP disclosed
US-4661620-A FROM CARBON MONOXIDE, OXYGEN AND A STYRENE WITH A CATALYST CONTAINING PLATINUM GROUP, COPPER OR IRON AND ADDITIONAL METAL COMPONENTS MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1987-04-28 US disclosed
EP-0177354-A2 Preparation process of cinnamate esters MITSUI TOATSU CHEMICALS, Inc. (JP) 1986-04-09 EP disclosed
US-4339429-A Toothpaste active against plaque comprising a copper compound and a plastic polishing agent BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) 1982-07-13 US disclosed
US-4332791-A NONDISCOLORING BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) 1982-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054882-A1 Diaryl ether condensation reactions NSFL1C, DERL1, UBE2M HDAC3 2112/4885HDAC4 1861/4885HDAC1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.